Table 4.

Fatty acid composition of LDL phosphatidylcholine from healthy subjects and type-2 diabetic patients.

Fatty acid	Healthy subjects		Type-2 diabetic patients
	mol%	nmol/mg protein	mol%	nmol/mg
16:0	33.0 ± 0.9	358.7 ± 16.7	34.2 ± 0.4	347.6 ± 9.5
16:1n-7	0.3 ± 0.1	3.7 ± 0.9	0.2 ± 0.1	2.3 ± 0.7
18:0	15.8 ± 0.5	154.8 ± 4.9	15.4 ± 0.8	142.9 ± 9.6
18:1n-7	1.4 ± 0.3	14.0 ± 2.3	1.3 ± 0.3	11.8 ± 2.5
18:1n-9	10.9 ± 0.5	108.4 ± 6.0	11.6 ± 0.4	108.0 ± 5.0
18:2n-6	22.0 ± 0.9	220.0 ± 14.1	19.4 ± 0.7*	181.9 ± 10.3*
18:3n-3	0.2 ± 0.0	1.5 ± 0.2	0.2 ± 0.1	2.0 ± 0.7
18:3n-6	0.1 ± 0.0	0.6 ± 0.2	0.0 ± 0.0	0.3 ± 0.2
20:3n-6	2.9 ± 0.2	26.7 ± 2.2	3.4 ± 0.3	29.3 ± 2.5
20:4n-6	7.8 ± 0.7	71.4 ± 5.6	9.1 ± 1.0	78.0 ± 7.7
20:5n-3	1.2 ± 0.4	10.3 ± 2.8	0.8 ± 0.2	7.0 ± 1.6
22:5n-3	0.3 ± 0.2	2.9 ± 1.4	0.3 ± 0.1	2.7 ± 0.9
22:6n-3	3.3 ± 0.5	27.6 ± 3.3	3.0 ± 0.2	24.3 ± 2.1
SFA	49.1 ± 1.0	516.7 ± 20.1	50.0 ± 0.8	493.7 ± 15.7
MUFA	13.2 ± 0.6	130.4 ± 7.4	13.5 ± 0.4	125.3 ± 4.5
PUFA	37.7 ± 0.8	361.1 ± 11.6	36.4 ± 0.8	326.1 ± 9.7

Values expressed as mole percent of main fatty acids and nmol/mg protein. are means ± S.E.M. of at least six subjects per group.

^*p ≤ 0.05 compared with LDL from healthy subjects. MUFA. monounsaturated fatty acids; PUFA. polyunsaturated fatty acids; SFA. saturated fatty acids.